BridgeBio Pharma (BBIO) Revenue & Revenue Breakdown
BridgeBio Pharma Revenue Highlights
Latest Revenue (Y)
$9.30M
Latest Revenue (Q)
$2.17M
Main Segment (Y)
License
Main Geography (Y)
License
BridgeBio Pharma Revenue by Period
BridgeBio Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $9.30M | -88.02% |
| 2022-12-31 | $77.65M | 11.38% |
| 2021-12-31 | $69.72M | 745.14% |
| 2020-12-31 | $8.25M | -79.66% |
| 2019-12-31 | $40.56M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
BridgeBio Pharma generated $9.30M in revenue during NA 2023, up -88.02% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
BridgeBio Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $2.17M | -98.97% |
| 2024-03-31 | $211.12M | 11998.57% |
| 2023-12-31 | $1.75M | -57.35% |
| 2023-09-30 | $4.09M | 149.30% |
| 2023-06-30 | $1.64M | -10.13% |
| 2023-03-31 | $1.83M | -2.35% |
| 2022-12-31 | $1.87M | 453.25% |
| 2022-09-30 | $338.00K | -99.54% |
| 2022-06-30 | $73.75M | 4253.36% |
| 2022-03-31 | $1.69M | -86.85% |
| 2021-12-31 | $12.89M | 449.74% |
| 2021-09-30 | $2.34M | -95.66% |
| 2021-06-30 | $54.02M | 11593.51% |
| 2021-03-31 | $462.00K | 278.69% |
| 2020-12-31 | $122.00K | -98.50% |
| 2020-09-30 | $8.13M | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $13.82M | -48.32% |
| 2019-09-30 | $26.74M | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
BridgeBio Pharma generated $2.17M in revenue during Q2 2024, up -98.97% compared to the previous quarter, and up 118.73% compared to the same period a year ago.
BridgeBio Pharma Revenue Breakdown
BridgeBio Pharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 | Dec 19 |
|---|---|---|
| License | $8.00M | $13.80M |
BridgeBio Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 20: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Sep 20 |
|---|---|---|---|---|---|---|---|
| License and Service | $1.83M | $338.00K | $73.75M | - | - | - | - |
| Product | - | - | - | $1.46M | $759.00K | $987.00K | - |
| License | - | - | - | $235.00K | $1.58M | $8.00M | - |
BridgeBio Pharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 23: License and Service (100.00%).
BridgeBio Pharma Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 19 |
|---|---|
| License | $13.80M |
BridgeBio Pharma's latest annual revenue breakdown by geography, as of Dec 19: License (100.00%).
Quarterly Revenue by Country
| Country | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Sep 20 |
|---|---|---|---|---|---|---|---|
| License and Service | $1.83M | $338.00K | $73.75M | - | - | - | - |
| Product | - | - | - | $1.46M | $759.00K | $987.00K | - |
| License | - | - | - | $235.00K | $1.58M | $8.00M | - |
BridgeBio Pharma's latest quarterly revenue breakdown by geography, as of Mar 23: License and Service (100.00%).
BridgeBio Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| BBIO | BridgeBio Pharma | $9.30M | $2.17M |
| KRTX | Karuna Therapeutics | $654.00K | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| CERE | Cerevel Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| TERN | Terns Pharmaceuticals | - | - |
BBIO Revenue FAQ
What is BridgeBio Pharma’s yearly revenue?
BridgeBio Pharma's yearly revenue for 2023 was $9.3M, representing a decrease of -88.02% compared to 2022. The company's yearly revenue for 2022 was $77.65M, representing an increase of 11.38% compared to 2021. BBIO's yearly revenue for 2021 was $69.72M, representing an increase of 745.14% compared to 2020.
What is BridgeBio Pharma’s quarterly revenue?
BridgeBio Pharma's quarterly revenue for Q2 2024 was $2.17M, a -98.97% decrease from the previous quarter (Q1 2024), and a 32.11% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $211.12M, a 11998.57% increase from the previous quarter (Q4 2023), and a 11461.88% increase year-over-year (Q1 2023). BBIO's quarterly revenue for Q4 2023 was $1.74M, a -57.35% decrease from the previous quarter (Q3 2023), and a -6.68% decrease year-over-year (Q4 2022).
What is BridgeBio Pharma’s revenue growth rate?
BridgeBio Pharma's revenue growth rate for the last 3 years (2021-2023) was -86.66%, and for the last 5 years (2019-2023) was -77.06%.
What are BridgeBio Pharma’s revenue streams?
BridgeBio Pharma's revenue streams in c 20 are License
What is BridgeBio Pharma’s main source of revenue?
For the fiscal year ending Dec 20, the largest source of revenue of BridgeBio Pharma was License. This segment made a revenue of $8M, representing 100.00% of the company's total revenue.